US 2023/0148332 A1 · VACCINE ADJUVANTS

Abstract

A compound comprising a structure of Compound 1, or prodrug thereof, salt thereof, or tautomer, polymorph, solvate, or combination thereof, can be used as an adjuvant in vaccines. The Compound 1 can be used in: methods of performing a vaccination; methods of agonizing a TLR 7 and/or TLR 8; and/or methods of activating an immune system.

Claims37

Dependent claims

A compound comprising a structure of Compound 1,

Dependencies are inferred from the claim text.

Facts

Application

17/918,249Filed 4 May 2021

Priority

5 May 2020

Published

11 May 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

A61K 39/39
Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 31/12
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antivirals
A61P 31/14
Antivirals: for RNA viruses

Vaccine adjuvants

Life of this patent

Abstract

Claims37

Vaccine adjuvants

Life of this patent

Abstract

Claims37